The inclusion of six population-based cohorts from diverse geographical settings enhances the generalizability of the findings. The authors also remarked that, The median follow-up period of 1.8 to 3.0 years is insufficient to evaluate long-term risks. In addition, the studys focus on populations with type 2 diabetes may limit is applicability to non-diabetic populations, a growing group of GLP-1RA users, particularly for obesity management. About the Journal Thyroid , the official journal of the American Thyroid Association , (ATA ) is an authoritative peer-reviewed journal published monthly online with open access options and in print
Pivotal clinical trials in continuous ketone monitoring, akin to currently available continuous glucose monitoring, are taking place in 2023 [53]
However, the certainty of this finding was low due to limitations in study design and execution of the trials
However, medication costs through telehealth can be high, especially for brand-name GLP-1 drugs
112 However, in recent years, the FDA has introduced the patient-focused drug development initiative, where patient-reported outcomes such as improvements in quality of life and healthy life years in MASH patients following treatment can serve as trial endpoints, potentially influencing final approval based on these data